WynnVision, a biomedical nanofilms company based in the Virginia Bio+Tech Center in downtown Richmond, has received a $1.5 million grant for research to help prevent infections associated with medical devices.
The grant from the National Heart, Lung, and Blood Institute is part of the National Institutes of Health’s Small Business Innovation Research FastTrack program designed to encourage small businesses to engage in research and development.
This funding follows a $225,000 award to the company in August 2018 to develop a new approach to reduce the incidence of ventilator-associated pneumonia and ventilator-related infections. The approach, led by WynnVision Senior Chemist Olga Zolotarskaya, does not use antibiotics or antimicrobials that can lead to “super-bugs.”
The new funding will be used for research on preventing infections due to endotracheal tubes.
“WynnVision was able to achieve milestones set in our Phase I grant, and the team is looking forward to continuing work in eliminating infections with comfort and safety for patients,” said Dr. Kenneth Wynne, founder and CEO of WynnVision.